Juan Carlos Zúñiga-Pflücker, PhD

Juan Carlos Zúñiga-Pflücker, Ph.D. Scientific Advisory Board Member, Praespero Professor, Department of Immunology, Temerty Faculty of Medicine, University of Toronto; Senior Scientist, Sunnybrook Research Institute
Key Achievements
Authored 299 publications between 1988 and 2025
Founder of ProTgen, a biotechnology company developing targeted Notch activators to reactivate the thymus and rebuild the adaptive immune system
Recipient of the AAI Distinguished Service Award (2020)
Recipient of the John D. Reynolds Award (2022) for exceptional service to the Canadian Society for Immunology
Discovered that Notch signaling is a key factor in artificially producing therapeutic T cells, a finding that led to the founding of Notch Therapeutics
Leading Praespero-supported work to generate regulatory T cells from human pluripotent stem cells
ABOUT
A leader in T cell development and translational immunology, Juan Carlos Zúñiga-Pflücker investigates how the body builds its adaptive immune system and how that process can be harnessed to treat disease. He later served as Chair of the Department of Immunology at the University of Toronto, and he continues to run his lab at the University of Toronto and Sunnybrook Research Institute.
His team's discovery that Notch signaling, a pathway central to T cell development, can be used to produce therapeutic T cells artificially opened the door to cell-based therapies. He co-founded Notch Therapeutics to bring this work to patients, and has since founded ProTgen, which develops targeted Notch activators designed to restore the thymus and rebuild immune competence in people whose immune systems are weakened by cancer treatment, immunodeficiency, or aging.
Beyond the lab, Dr. Zúñiga-Pflücker is deeply committed to the scientific community, serving the Canadian Society for Immunology and helping to host the 2028 International Union of Immunological Societies conference in Toronto, which will bring immunologists from around the world together. On Praespero's Scientific Advisory Board, he brings the pioneering, boundary-pushing thinking that Praespero exists to support.
With Praespero's funding, Dr. Zúñiga-Pflücker's team is working to make regulatory T cells, the cells that can switch off harmful autoimmune responses, from human pluripotent stem cells. While stem cells are known to yield T cells, the challenge has been producing the right kind, with the potency to shut down an autoimmune attack. Their goal is a cell-based therapy that could one day help end autoimmune disease. Praespero's support, including its networking opportunities, has helped keep the work moving and led to a postdoctoral fellowship from the Cancer Research Institute to support a new researcher in his lab. The team is now drafting manuscripts and has published a literature review of the field.
Dr. Zúñiga-Pflücker earned his bachelor's degree in Zoology from the University of Maryland and his Ph.D. in Genetics and Immunology from George Washington University. Although he first planned to study developmental biology, working in a lab at the National Institutes of Health led him to a lasting passion for T cell development.
